CytoDyn Inc. (OTCPK: CYDY)
Health Care · Biotechnology · US
$0.21
+10.73% today · -32.3% 1Y
CytoDyn Inc. (OTCPK: CYDY) operates in the Biotechnology industry within the Health Care sector. The company is valued at $288.40M and employs 13 people.
Over the last twelve months the share price has lost 32.3%, trading between 0.18 and 0.40.
Tweenvest scores CytoDyn Inc. across four factors: quality 17/100. Its strongest factor is quality.
CYDY price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $288.40M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.04
- Dividend yield
- —
- Beta (5Y)
- 1.21
- 52-week high
- $0.40
- 52-week low
- $0.18
- Avg volume (3M)
- —
- Shares outstanding
- 1.37B
- Employees
- 13
- Next earnings
- —
About CytoDyn Inc.
CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored for its potential applications in human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), various oncological diseases, and coronavirus disease (COVID-19). In addition, leronlimab is undergoing a Phase 1b/2 clinical investigation specifically for metastatic triple-negative breast cancer. Established in 2002, and previously operating as RexRay Corporation, CytoDyn Inc. is headquartered in Vancouver, Washington.
- ISIN
- US23283M1018
- Founded
- 2002
- Listed since
- Dec 13, 2006
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $263.50 | -0.55% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.25 | +0.21% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $145.32 | -0.55% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.33 | +0.05% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $825.06 | -1.08% |
| argenx SEENXTBR: ARGX | $65.85B | €867.40 | -3.84% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $135.44 | -6.64% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.